We used these three indicators to divide all BC patients into luminal A (ER+, PR±, HER2−), luminal B (ER+, PR±, HER2+), HER2+ (ER−, PR−, HER2+), and TNBC (ER−, PR−, HER2−) subtypes, and these groups included 373, 99, 37, and 116 patients, respectively. This evidence concerns the gene ERBB2 and breast cancer.